apixaban우선순위 중간ICSR 검토체계적 문헌고찰리뷰
LITERATURE DETAIL · PMID 42622790
Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Thrombosis: An Indication-Stratified Systematic Review and Meta-Analysis of Treatment and Postoperative Prophylaxis.
Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Thrombosis: An Indication-Stratified Systematic Review and Meta-Analysis of Treatment and Postoperative Prophylaxis.
- 저자
- Chao Huang, Shoufang Li, Jianping He
- 저널
- Cardiovascular drugs and therapy
- 공개일
- 2026 Aug 20
- 연구 유형
- 체계적 문헌고찰, 리뷰
- DOI
- 10.1007/s10557-026-07908-0
문헌 요약
Apixaban is increasingly used as an alternative to low-molecular-weight heparin (LMWH) in patients with cancer, but evidence spans distinct clinical settings, including treatment of established cancer-associated thrombosis/venous thromboembolism (CAT/VTE) and postoperative thromboprophylaxis. We performed an indication-stratified systematic review and met…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.